New US FDA guidance clarifies compliance requirements for clinical trial sponsors, investigators and IRBs whose studies fall under both agency and Department of Health and Human Services (HHS) requirements.
The guidance focuses on differences in human subject protection requirements between HHS and FDA clinical investigation regulations.
